Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML?

(MedPage Today) -- For patients with chronic-phase chronic myeloid leukemia (CML), a response-based dose-reduction strategy for ponatinib (Iclusig) may limit its toxicity while maintaining or improving efficacy, a retrospective study suggested...